Human VEGFR3/Flt-4 Biotinylated Antibody Summary
Tyr25-Ile776
Accession # P35916
Applications
Human VEGFR3/Flt-4 Sandwich Immunoassay
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: VEGFR3/Flt-4
VEGFR2 (KDR/Flk-1), VEGFR1 (Flt-1) and VEGFR3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGF R1, 2, and 3 is almost exclusively restricted to the endothelial cells. These receptors are likely to play essential roles in vasculogenesis and angiogenesis.
VEGFR3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain, and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGFR3 (Flt-4). VEGFR3 is widely expressed in the early embryo but becomes restricted to lymphatic endothelia at later stages of development. It is likely that VEGFR3 may be important for lymph angiogenesis.
Product Datasheets
Citations for Human VEGFR3/Flt-4 Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
4
Citations: Showing 1 - 4
Filter your results:
Filter by:
-
Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
Authors: Mouawad R, Spano JP, Comperat E, Capron F, Khayat D
Eur. J. Cancer, 2009-01-20;45(8):1407-14.
Species: Human
Sample Types: Serum
Applications: ELISA Development -
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels.
Authors: Riccioni R, Senese M, Diverio D, Riti V, Mariani G, Boe A, LoCoco F, Foa R, Peschle C, Sporn M, Testa U
Leuk. Res., 2008-03-04;32(8):1244-58.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts.
Authors: Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E, Petrucci E, Cedrone M, Lo-Coco F, Foa R, Peschle C, Testa U
Stem Cells, 2007-04-19;25(8):1862-71.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis.
Authors: Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, Guba M
Kidney Int., 2007-02-14;71(8):771-7.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human VEGFR3/Flt-4 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Human VEGFR3/Flt-4 Biotinylated Antibody and earn rewards!
Have you used Human VEGFR3/Flt-4 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
